Inflammation and treatment response in AML
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how inflammation (the body's response to injury or infection) affects treatment outcomes in people with acute myeloid leukemia (AML). If you have a new diagnosis or have stored samples from a past diagnosis, you may help researchers understand why some people respond better to therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have a new diagnosis of acute myeloid leukemia (AML) or have stored samples from a past AML diagnosis
- You can understand and sign a consent form for participating in this research study
- You are willing to have your bone marrow or blood samples used for research
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at how infections affect people with acute myeloid leukemia (AML). If you qualify, your experiences will help doctors better understand and manage infections in AML patients.
This study looks at how adults with acute myeloid leukemia (AML) are treated and how they fare over time. The goal is to better understand the disease and improve care.
This trial looks at how childhood, teen, and young adult acute myeloid leukemia (AML) changes at the genetic level and how cells respond to multiple drugs. It may help doctors understand which treatments work best and how leukemia interacts with supportive cells in the bone marrow.
This study compares different treatment intensities for adults with acute myeloid leukemia (AML) who are less able to handle strong chemotherapy. It aims to find the best approach for people with health issues like heart or lung problems that make standard chemo riskier.
This study uses blood samples from people with acute myeloid leukemia (AML) and from healthy stem cell donors to learn how to make immune cells better at killing cancer. The goal is to develop a new type of treatment that helps the body's own defenses fight the disease.
This trial tests a new type of maintenance therapy for acute myeloid leukemia (AML) patients who have already responded well to chemotherapy. The treatment uses your own immune cells to help prevent the cancer from coming back.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.